Effects of Canagliflozin on Patients with Type 2 Diabetes on Peritoneal Dialysis
Study Overview
Patients with type 2 diabetes (T2D) who are on dialysis face a higher risk of death due to heart and blood vessel issues. This study looks at how a medication called canagliflozin, which is used for T2D, affects heart health in these patients.
Study Design
The CARD-PD study is a multi-center trial that will compare the effects of canagliflozin with a control treatment in patients with T2D on peritoneal dialysis. Here are the key points:
- Participants will be randomly assigned to either receive canagliflozin (100 mg/day) or a delayed-start control for 6 months.
- We aim to enroll 36 participants, with 18 in each group.
- The main focus will be on measuring plasma brain natriuretic peptide (BNP) levels after 6 months.
- After the initial phase, all participants will receive canagliflozin for an extended period.
Ethics and Results Sharing
The study has been approved by the Ethics Review Board at Hokkaido University Hospital. Results will be shared in scientific journals and conferences.
Importance of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, helps clinicians by providing easy access to clinical guidelines and research.
Enhancing Patient Care
In today’s healthcare system, improving efficiency is vital. Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, simplifying patient management.
Learn More
Discover how our solutions can improve workflows and patient outcomes at aidevmd.com.
